| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
|
Science
|
2011
|
7.95
|
|
2
|
Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome.
|
Liver Transpl
|
2004
|
1.95
|
|
3
|
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
|
J Clin Oncol
|
2003
|
1.88
|
|
4
|
Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study.
|
Cancer
|
2010
|
1.18
|
|
5
|
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.
|
Clin Cancer Res
|
2013
|
1.16
|
|
6
|
Phase I trial of combretastatin a-4 phosphate with carboplatin.
|
Clin Cancer Res
|
2005
|
1.12
|
|
7
|
Systemic and targeted therapy for advanced colon cancer.
|
Expert Rev Gastroenterol Hepatol
|
2008
|
1.12
|
|
8
|
Advanced local therapies for the treatment of limited systemic mCRC.
|
Oncology (Williston Park)
|
2014
|
1.07
|
|
9
|
Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol.
|
Cancer
|
2010
|
0.98
|
|
10
|
Cancer immunotherapy in clinical practice -- the past, present, and future.
|
Chin J Cancer
|
2014
|
0.98
|
|
11
|
Neoadjuvant therapy with imatinib mesylate for locally advanced GI stromal tumor.
|
Gastrointest Endosc
|
2005
|
0.89
|
|
12
|
Isocitrate dehydrogenase-1 is mutated in inflammatory bowel disease-associated intestinal adenocarcinoma with low-grade tubuloglandular histology but not in sporadic intestinal adenocarcinoma.
|
Am J Surg Pathol
|
2014
|
0.84
|
|
13
|
Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
|
Am J Surg Pathol
|
2016
|
0.83
|
|
14
|
Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study.
|
Am J Clin Oncol
|
2011
|
0.82
|
|
15
|
Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future.
|
Curr Treat Options Oncol
|
2014
|
0.82
|
|
16
|
Developments in treatment of esophageal/gastric cancer.
|
Curr Treat Options Oncol
|
2009
|
0.81
|
|
17
|
Esophageal cancer in a young woman with bulimia nervosa: a case report.
|
J Med Case Rep
|
2007
|
0.80
|
|
18
|
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer.
|
Cancer Chemother Pharmacol
|
2013
|
0.80
|
|
19
|
Hepatocellular carcinoma: prevention and therapy.
|
Curr Oncol Rep
|
2011
|
0.79
|
|
20
|
Oxaliplatin-associated hypersensitivity reactions: clinical presentation and management.
|
Clin Colorectal Cancer
|
2006
|
0.79
|
|
21
|
Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer.
|
Cancer
|
2013
|
0.78
|
|
22
|
Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
|
Clin Cancer Res
|
2002
|
0.77
|
|
23
|
Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival.
|
Am J Surg Pathol
|
2015
|
0.77
|
|
24
|
Neoadjuvant Treatment for Surgically Resectable Metastatic Colorectal Cancer: Is There an Optimal Succession?
|
Oncology (Williston Park)
|
2016
|
0.76
|
|
25
|
Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer.
|
Cancer
|
2003
|
0.75
|
|
26
|
Recent advances in colorectal cancer therapy.
|
Cancer Biol Ther
|
2003
|
0.75
|
|
27
|
Adjuvant therapy for gastric cancer: how negative results can help patients.
|
J Natl Cancer Inst
|
2007
|
0.75
|
|
28
|
Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma?
|
Nat Clin Pract Oncol
|
2008
|
0.75
|
|
29
|
Recombinant human granulocyte macrophage colony stimulating factor in deep second-degree burn wound healing.
|
Medicine (Baltimore)
|
2017
|
0.75
|
|
30
|
Cancers of the large bowel and hepatobiliary tract.
|
Cancer Chemother Biol Response Modif
|
2005
|
0.75
|
|
31
|
General assessment of the patient with cancer for the interventional oncologist.
|
J Vasc Interv Radiol
|
2006
|
0.75
|
|
32
|
What is the reference cytotoxic regimen for advanced gastric cancer: standard versus optimal therapy?
|
Expert Rev Anticancer Ther
|
2011
|
0.75
|